Omeros(OMER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OMER Omeros

Closed 11-12 16:00:00 EST

17.99

-0.16

-0.88%

盘后17.99

+0.000.00%

19:30 EST

High18.13	Low17.38	Vol810.08K
Open17.90	D1 Closing18.15	Amplitude4.13%
Mkt Cap1.30B	Tradable Cap1.23B	Total Shares72.38M
T/O14.51M	T/O Rate1.19%	Tradable Shares68.26M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OMER","market":"US","secType":"STK","nameCN":"Omeros","latestPrice":17.99,"timestamp":1794517200000,"preClose":18.15,"halted":0,"volume":810076,"hourTrading":{"tag":"盘后","latestPrice":17.99,"preClose":17.99,"latestTime":"19:30 EST","volume":33377,"amount":600464.77,"timestamp":1794529803527,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.008815426997245187,"floatShares":68258040,"shares":72375355,"eps":1.571234,"marketStatus":"Closed","change":-0.16,"latestTime":"11-12 16:00:00 EST","open":17.9,"high":18.13,"low":17.38,"amount":14511106.058139998,"amplitude":0.041322,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.571234,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794560400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1254974400000,"exchange":"NASDAQ","adjPreClose":18.15,"preHourTrading":{"tag":"盘前","latestPrice":17.87,"preClose":18.15,"latestTime":"09:29 EST","volume":3612,"amount":64947.10832400001,"timestamp":1794493799999,"change":-0.28,"changeRate":-0.015427,"amplitude":0.043526},"postHourTrading":{"tag":"盘后","latestPrice":17.99,"preClose":17.99,"latestTime":"19:30 EST","volume":33377,"amount":600464.77,"timestamp":1794529803527,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.960528,"impliedVol":0.8666,"impliedVolPercentile":0.5139},"requestUrl":"/m/hq/s/OMER/tweets","defaultTab":"tweets","newsList":[{"id":"2682430617","title":"Is Omeros (OMER) Undervalued Following Its November 16 Results Catalyst?","url":"https://stock-news.laohu8.com/highlight/detail?id=2682430617","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682430617?lang=en_us&edition=fundamental","pubTime":"2026-11-11 19:25","pubTimestamp":1794396313,"startTime":"0","endTime":"0","summary":"SSasha JovanovicNovember 11, 2026","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/is-omeros-omer-undervalued-following-its-november-16-results","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/is-omeros-omer-undervalued-following-its-november-16-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["OMER","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682345459","title":"Omeros Sets Third-Quarter Financial Results Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2682345459","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682345459?lang=en_us&edition=fundamental","pubTime":"2026-11-11 05:04","pubTimestamp":1794344642,"startTime":"0","endTime":"0","summary":"Omeros Sets Third-Quarter Financial Results AnnouncementOmeros will release third-quarter 2026 financial results on Nov. 16, 2026, after market close.Management will host a conference call and webcast","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261110:nNDLc8cpJ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679294228","title":"Omeros Grants CEO New Performance-Based Stock Options","url":"https://stock-news.laohu8.com/highlight/detail?id=2679294228","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679294228?lang=en_us&edition=fundamental","pubTime":"2026-10-31 05:39","pubTimestamp":1793396359,"startTime":"0","endTime":"0","summary":"Omeros ( ($OMER) ) has shared an update. On October 28, 2026, Omeros’ board compensation committee granted CEO Gregory A. Demopulos a performance-b...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/omeros-grants-ceo-new-performance-based-stock-options?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/omeros-grants-ceo-new-performance-based-stock-options?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679724240","title":"Omeros Grants CEO Demopulos Performance-Based Options for up to 500,000 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2679724240","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679724240?lang=en_us&edition=fundamental","pubTime":"2026-10-31 05:02","pubTimestamp":1793394169,"startTime":"0","endTime":"0","summary":"Omeros Grants CEO Demopulos Performance-Based Options for Up to 500,000 SharesOmeros granted CEO Gregory A. Demopulos a performance-based stock option award covering up to 500,000 shares on October 28","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261030:nNDL7lW7v0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678159298","title":"Is EMA Drug Rejection Altering The Investment Case For Omeros (OMER)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2678159298","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678159298?lang=en_us&edition=fundamental","pubTime":"2026-10-26 13:27","pubTimestamp":1792992458,"startTime":"0","endTime":"0","summary":"Omeros reported that the EMA’s Committee for Medicinal Products for Human Use maintained a negative opinion on narsoplimab for TA-TMA in Europe after re-examination, limiting near term access to an approved therapy in that region, while YARTEMLEA remains available in the U.S. for patients aged two and older.\nThe firm plans to end its European compassionate-use program to prioritize growing U.S. commercial demand for YARTEMLEA. This concentrates resources on an active revenue channel but...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/is-ema-drug-rejection-altering-the-investment-case-for-omero","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/is-ema-drug-rejection-altering-the-investment-case-for-omero","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","BK6045","PA3.SI","OMER","BK6512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678642189","title":"Omeros (OMER) Faces An EMA Setback, Is It Still 40% Below Fair Value?","url":"https://stock-news.laohu8.com/highlight/detail?id=2678642189","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678642189?lang=en_us&edition=fundamental","pubTime":"2026-10-25 09:29","pubTimestamp":1792891777,"startTime":"0","endTime":"0","summary":"Omeros (OMER) just absorbed a clear regulatory setback in Europe. The EMA’s CHMP upheld its negative view on narsoplimab for TA-TMA after re-examining the marketing application.\nAt a share price of US$16.57, Omeros has seen short term momentum fade, with the 30 day share price return down 17.48% and the 1 day move lower by 1.72%. However, the 90 day share price return of 46.12% and a very large 3 year total shareholder return of 1,434.26% show how sharply sentiment has swung around the stock...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/omeros-omer-faces-an-ema-setback-is-it-still-40-below-fair-v","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/omeros-omer-faces-an-ema-setback-is-it-still-40-below-fair-v","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676520498","title":"Why Omeros Stock Is Down 13.8% And What's Next After EU Drug Rejection","url":"https://stock-news.laohu8.com/highlight/detail?id=2676520498","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676520498?lang=en_us&edition=fundamental","pubTime":"2026-10-18 22:27","pubTimestamp":1792333654,"startTime":"0","endTime":"0","summary":"Omeros reported that the European Medicines Agency’s CHMP upheld its negative opinion on the marketing authorization application for narsoplimab in TA TMA after re-examination, while the drug remains FDA approved in the U.S. as YARTEMLEA for patients aged two and older.\nThe company plans to end its European compassionate use program for YARTEMLEA due to U.S. demand, which tightens near term supply options for TA TMA patients in Europe, even as Omeros pursues additional MASP 2 indications and...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/why-omeros-stock-is-down-138-and-whats-next-after-eu-drug-re","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/why-omeros-stock-is-down-138-and-whats-next-after-eu-drug-re","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["OMER","BK6045","BK6512","BK4007","PA3.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676410965","title":"Is Omeros (OMER) Undervalued After The EMA Upheld Its Narsoplimab Setback?","url":"https://stock-news.laohu8.com/highlight/detail?id=2676410965","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676410965?lang=en_us&edition=fundamental","pubTime":"2026-10-17 18:29","pubTimestamp":1792232976,"startTime":"0","endTime":"0","summary":"Omeros (OMER) is back in focus after the European Medicines Agency’s Committee for Medicinal Products for Human Use upheld a negative opinion on narsoplimab for TA-TMA, which prompted a sharp share-price reaction.\nThe EMA setback has triggered a sharp short-term reset, with the share price down 13.78% in the last day and 18.31% over the week. Yet Omeros still carries a 99.88% 1-year total shareholder return and a very large 3-year total shareholder return, so recent selling reflects a swing...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/is-omeros-omer-undervalued-after-the-ema-upheld-its-narsopli","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/is-omeros-omer-undervalued-after-the-ema-upheld-its-narsopli","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675955095","title":"EU Panel Upholds Negative Opinion on Omeros’ Narsoplimab Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2675955095","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675955095?lang=en_us&edition=fundamental","pubTime":"2026-10-16 18:20","pubTimestamp":1792146028,"startTime":"0","endTime":"0","summary":"EU Panel Upholds Negative Opinion on Omeros’ Narsoplimab ApplicationEMA's CHMP upheld its negative opinion on Omeros' narsoplimab marketing application following re-examination of its June 2026 decisi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nNDL3FzMGl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675595579","title":"Omeros Corporation - to Terminate Yartemlea Compassionate-Use Program in Europe Due to U.S. Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2675595579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675595579?lang=en_us&edition=fundamental","pubTime":"2026-10-16 18:20","pubTimestamp":1792146000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nTUAB47WK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675595570","title":"Omeros Corporation Receives Chmp Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in Ta-Tma","url":"https://stock-news.laohu8.com/highlight/detail?id=2675595570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675595570?lang=en_us&edition=fundamental","pubTime":"2026-10-16 18:20","pubTimestamp":1792146000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nTUAB47WK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675527595","title":"Omeros Corporation - Plans Clinical Studies in Ards and High-Risk Ta-Tma in Pediatric Patients Later This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2675527595","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675527595?lang=en_us&edition=fundamental","pubTime":"2026-10-16 18:20","pubTimestamp":1792146000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nTUAB47WK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675834592","title":"Omeros Price Target Maintained with a $22.00/Share by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2675834592","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675834592?lang=en_us&edition=fundamental","pubTime":"2026-10-14 18:54","pubTimestamp":1791975240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OMER/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672719741","title":"Omeros (OMER) Stock Looks Cheap After Its Huge Three Year Run","url":"https://stock-news.laohu8.com/highlight/detail?id=2672719741","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672719741?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:23","pubTimestamp":1790936609,"startTime":"0","endTime":"0","summary":"Omeros Corporation has delivered a very large share price gain over the past few years, which now puts a spotlight on whether that move is supported by its earnings power. After such a strong run, the question for anyone looking at Omeros today is whether the current market value lines up with what the business is actually earning.\n\nOmeros has returned about 571.6% over the past 3 years, which puts real pressure on the current earnings profile to justify that kind of share price reset.\nThe...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/omeros-omer-stock-looks-cheap-after-its-huge-three-year-run","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/omeros-omer-stock-looks-cheap-after-its-huge-three-year-run","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RGLO","DECU","OMER","GXDW","JOYT","VGFPF","PMDE","VOTE","BK4007","FEBU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671008982","title":"Alessio Olmi Reiterates Buy on OMER, Lifts Estimates and Sets €5.1 Target Price on Strong 2026 Results and Undervalued Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2671008982","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671008982?lang=en_us&edition=fundamental","pubTime":"2026-09-30 21:35","pubTimestamp":1790775330,"startTime":"0","endTime":"0","summary":"Alessio Olmi, an analyst from TP ICAP MIDCAP, reiterated the Buy rating on OMER S.p.a.. The associated price target is €5.10. Alessio Olmi has give...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/alessio-olmi-reiterates-buy-on-omer-lifts-estimates-and-sets-e5-1-target-price-on-strong-2026-results-and-undervalued-valuation-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/alessio-olmi-reiterates-buy-on-omer-lifts-estimates-and-sets-e5-1-target-price-on-strong-2026-results-and-undervalued-valuation-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670411557","title":"Omeros VP Finance & CAO David J. Borges Reports Disposal of USD 419,000 Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2670411557","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670411557?lang=en_us&edition=fundamental","pubTime":"2026-09-25 09:01","pubTimestamp":1790298091,"startTime":"0","endTime":"0","summary":"Omeros VP Finance & CAO David J. Borges reports disposal of USD 419,000 common sharesOmeros VP, Finance and CAO David J. Borges reported option exercises and open-market sales on Sept. 22-23, 2026.Sol","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nNDL7pyW6l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Omeros VP Finance & CAO David J. Borges Reports Disposal of USD 419,000 Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669712196","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2669712196","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669712196?lang=en_us&edition=fundamental","pubTime":"2026-09-23 02:39","pubTimestamp":1790102373,"startTime":"0","endTime":"0","summary":"Napo Pharmaceuticals, part of Jaguar Health , said Tuesday the US Food and Drug Administration has granted a waiver of the fee associated with the Prescription Drug User Fee Act for Mytesi for fiscal 2027.Shares surged 350% as intraday trading volume catapulted to over 9.8 million from a daily average of about 29,000.Omeros  shares jumped 13% amid heavy trading after Cantor Fitzgerald upgraded the stock to overweight from neutral.Over 2.78 million shares traded intraday versus a daily average of roughly 1.94 million.Silvia , formerly ProCap Financial, said its corporate name change is effective, and its common stock and warrants began trading on Tuesday on the Nasdaq Global Market.Shares climbed 15% as intraday trading volume surged to over 2.5 million.Price: 12.19, Change: +9.52, Percent Change: +356.37","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["JAGX","BK4007","SVIA","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669129007","title":"Omeros Shares Rise After Cantor Fitzgerald Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2669129007","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669129007?lang=en_us&edition=fundamental","pubTime":"2026-09-23 02:14","pubTimestamp":1790100875,"startTime":"0","endTime":"0","summary":"Omeros (OMER) shares were up over 12% in Tuesday trading after Cantor Fitzgerald upgraded the stock to overweight from neutral.Trading volume stood at more than 2.5 million shares, against a daily average of about 1.9 million.Price: 20.84, Change: +2.35, Percent Change: +12.71","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669114192","title":"Cantor upgrades Omeros on better than expected Yartemlea launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2669114192","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669114192?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:56","pubTimestamp":1790078194,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald upgraded Omeros (OMER) to Overweight from Neutral with a $22 price target The left the company’s Q2 report with the belief that Y...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cantor-upgrades-omeros-on-better-than-expected-yartemlea-launch-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cantor-upgrades-omeros-on-better-than-expected-yartemlea-launch-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669143069","title":"Omeros upgraded to Overweight from Neutral at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2669143069","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669143069?lang=en_us&edition=fundamental","pubTime":"2026-09-22 18:05","pubTimestamp":1790071521,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Olivia Brayer Saunders upgraded Omeros (OMER) to Overweight from Neutral with a $22 price target Published first on TheFl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/omeros-upgraded-to-overweight-from-neutral-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/omeros-upgraded-to-overweight-from-neutral-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.omeros.com","stockEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":-0.0754},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.4816},{"period":"1year","weight":1.6343},{"period":"ytd","weight":0.0568}],"compareEarnings":[{"period":"1week","weight":-0.0091},{"period":"1month","weight":-0.0235},{"period":"3month","weight":-0.0232},{"period":"6month","weight":0.0279},{"period":"1year","weight":0.1125},{"period":"ytd","weight":0.1142}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.352941,"avgChangeRate":-0.012739},{"month":2,"riseRate":0.588235,"avgChangeRate":0.056959},{"month":3,"riseRate":0.588235,"avgChangeRate":0.084424},{"month":4,"riseRate":0.411765,"avgChangeRate":-0.00729},{"month":5,"riseRate":0.352941,"avgChangeRate":-0.04488},{"month":6,"riseRate":0.294118,"avgChangeRate":0.025891},{"month":7,"riseRate":0.470588,"avgChangeRate":0.076019},{"month":8,"riseRate":0.352941,"avgChangeRate":0.006955},{"month":9,"riseRate":0.352941,"avgChangeRate":-0.000843},{"month":10,"riseRate":0.470588,"avgChangeRate":-0.041434},{"month":11,"riseRate":0.611111,"avgChangeRate":0.22207},{"month":12,"riseRate":0.529412,"avgChangeRate":0.065706}],"exchange":"NASDAQ","name":"Omeros","nameEN":"Omeros"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Omeros(OMER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Omeros(OMER) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Omeros,OMER,Omeros股票,Omeros股票老虎,Omeros股票老虎国际,Omeros行情,Omeros股票行情,Omeros股价,Omeros股市,Omeros股票价格,Omeros股票交易,Omeros股票购买,Omeros股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Omeros(OMER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Omeros(OMER) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}